L Y McGirt1,2, C A Degesys3, V E Johnson2, J A Zic2, J P Zwerner2, C M Eischen4,5. 1. Department of Hematology/Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA. 2. Department of Medicine/Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Dermatology, Baylor College of Medicine, Houston, TX, USA. 4. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Cancer Biology and the Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University Philadelphia, PA, USA.
Abstract
BACKGROUND: Cutaneous T-cell lymphomas (CTCL) are skin malignancies including mycosis fungoides (MF) and CD30(+) lymphoproliferative disorders (LPD). In early disease, CTCL can be difficult to diagnose, especially in MF for which there is no reliable diagnostic marker. MF/CTCL have increased expression of thymocyte selection-associated HMG box protein (TOX). Although TOX has been proposed to be a diagnostic marker for MF, further validation studies are needed. Moreover, it is unclear what drives TOX expression or its role in MF/CTCL. OBJECTIVE: We hypothesize evaluation of TOX levels across a spectrum of CTCL, including MF precursor (large plaque parapsoriasis, LPP), will help elucidate the implications of altered TOX expression. MATERIALS AND METHODS: TOX staining was performed in MF, CD30(+) LPD, LPP as well as benign inflammatory dermatoses (BID) and normal skin (NS). CTCL cell lines were utilized to evaluate the regulation of TOX. RESULTS: Positive TOX expression was identified in 73.6% of MF cases and in 31.6% of BID/NS. TOX had a positive predictive value (PPV) for MF of 86.7% and a negative predictive value (NPV) of 48.1%. TOX expression in MF was detected more commonly in Black patients (P = 0.015) and less commonly in transformed MF (P = 0.045). LPP had positive TOX staining in 70.0%. In CTCL cells, GATA3 knockdown decreased TOX mRNA and protein expression. TOX expression also decreased in the presence of CTCL therapeutics. CONCLUSION: Our data indicate that TOX is useful as a diagnostic marker in MF. Moreover, TOX expression was evident in LPP, indicating it may have a previously unappreciated role in the development of MF. Finally, our data suggest that GATA3 regulates TOX, revealing insight into TOX regulation.
BACKGROUND:Cutaneous T-cell lymphomas (CTCL) are skin malignancies including mycosis fungoides (MF) and CD30(+) lymphoproliferative disorders (LPD). In early disease, CTCL can be difficult to diagnose, especially in MF for which there is no reliable diagnostic marker. MF/CTCL have increased expression of thymocyte selection-associated HMG box protein (TOX). Although TOX has been proposed to be a diagnostic marker for MF, further validation studies are needed. Moreover, it is unclear what drives TOX expression or its role in MF/CTCL. OBJECTIVE: We hypothesize evaluation of TOX levels across a spectrum of CTCL, including MF precursor (large plaque parapsoriasis, LPP), will help elucidate the implications of altered TOX expression. MATERIALS AND METHODS:TOX staining was performed in MF, CD30(+) LPD, LPP as well as benign inflammatory dermatoses (BID) and normal skin (NS). CTCL cell lines were utilized to evaluate the regulation of TOX. RESULTS: Positive TOX expression was identified in 73.6% of MF cases and in 31.6% of BID/NS. TOX had a positive predictive value (PPV) for MF of 86.7% and a negative predictive value (NPV) of 48.1%. TOX expression in MF was detected more commonly in Black patients (P = 0.015) and less commonly in transformed MF (P = 0.045). LPP had positive TOX staining in 70.0%. In CTCL cells, GATA3 knockdown decreased TOX mRNA and protein expression. TOX expression also decreased in the presence of CTCL therapeutics. CONCLUSION: Our data indicate that TOX is useful as a diagnostic marker in MF. Moreover, TOX expression was evident in LPP, indicating it may have a previously unappreciated role in the development of MF. Finally, our data suggest that GATA3 regulates TOX, revealing insight into TOX regulation.
Authors: Laura Y McGirt; Clare M Adams; Devin A Baerenwald; Jeffrey P Zwerner; John A Zic; Christine M Eischen Journal: J Invest Dermatol Date: 2013-11-07 Impact factor: 8.551
Authors: Yuanshen Huang; Ivan V Litvinov; Yang Wang; Ming-Wan Su; Ping Tu; Xiaoyan Jiang; Thomas S Kupper; Jan P Dutz; Denis Sasseville; Youwen Zhou Journal: Oncotarget Date: 2014-06-30
Authors: Katharina Rindler; Wolfgang M Bauer; Constanze Jonak; Matthias Wielscher; Lisa E Shaw; Thomas B Rojahn; Felix M Thaler; Stefanie Porkert; Ingrid Simonitsch-Klupp; Wolfgang Weninger; Marius E Mayerhoefer; Matthias Farlik; Patrick M Brunner Journal: Front Immunol Date: 2021-04-21 Impact factor: 7.561
Authors: Enrique Huanosta-Murillo; Marcela Alcántara-Hernández; Brenda Hernández-Rico; Georgina Victoria-Acosta; Patricia Miranda-Cruz; María Antonieta Domínguez-Gómez; Fermín Jurado-Santacruz; Genaro Patiño-López; Vadim Pérez-Koldenkova; Alam Palma-Guzmán; Paula Licona-Limón; Ezequiel M Fuentes-Pananá; Alicia Lemini-López; Laura C Bonifaz Journal: Front Immunol Date: 2021-06-16 Impact factor: 7.561